An Open-label, Sequential Dosing, Single Ascending Dose (SAD) Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of KSHN001126 in Healthy Human Post-Menopausal Female Volunteers
Latest Information Update: 11 Jul 2024
At a glance
- Drugs KSHN 001126 (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Shivanka Research
Most Recent Events
- 25 Jun 2024 New trial record